FDA status: Semaglutide is FDA-approved
Unlike a broken bone that follows a predictable recovery arc, shoulder soft tissue injuries often linger for months or even years
No mortality attributable to the peptide has been reported in published animal studies, even at doses far exceeding effective doses (up to 10 mg/kg)
Zlatar, M., Kokot, A., Vuleti, L., Masnec, S., Kralj, T., Peria, M., Barii, I., Radi, B., Milanovi, K., Drmic, D., Seiwerth, S., & Sikiric, P
Its operational
While BPC-157 shows no strong evidence of tolerance or receptor desensitization in most reports (unlike some growth hormone-releasing peptides), cycling is still utilized for safety, sustainability, and optimization